Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2002 2
2005 3
2006 2
2007 1
2009 1
2011 2
2012 6
2013 4
2015 2
2018 1
2019 2
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb.
Wollenberg A, Howell MD, Guttman-Yassky E, Silverberg JI, Kell C, Ranade K, Moate R, van der Merwe R. Wollenberg A, et al. Among authors: moate r. J Allergy Clin Immunol. 2019 Jan;143(1):135-141. doi: 10.1016/j.jaci.2018.05.029. Epub 2018 Jun 12. J Allergy Clin Immunol. 2019. PMID: 29906525 Free article. Clinical Trial.
A Randomized Phase I Study of the Anti-Interleukin-33 Antibody Tozorakimab in Healthy Adults and Patients With Chronic Obstructive Pulmonary Disease.
Reid F, Singh D, Albayaty M, Moate R, Jimenez E, Sadiq MW, Howe D, Gavala M, Killick H, Williams A, Krishnan S, Godwood A, Shukla A, Hewitt L, Lei A, Kell C, Pandya H, Newcombe P, White N, Scott IC, Cohen ES. Reid F, et al. Among authors: moate r. Clin Pharmacol Ther. 2024 Mar;115(3):565-575. doi: 10.1002/cpt.3147. Epub 2024 Jan 24. Clin Pharmacol Ther. 2024. PMID: 38115209 Clinical Trial.
A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2.
Wilkinson T, De Soyza A, Carroll M, Chalmers JD, Crooks MG, Griffiths G, Shankar-Hari M, Ho LP, Horsley A, Kell C, Lara B, Mishra B, Moate R, Page C, Pandya H, Raw J, Reid F, Saralaya D, Scott IC, Siddiqui S, Ustianowski A, van Zuydam N, Woodcock A, Singh D. Wilkinson T, et al. Among authors: moate r. ERJ Open Res. 2023 Oct 2;9(5):00249-2023. doi: 10.1183/23120541.00249-2023. eCollection 2023 Sep. ERJ Open Res. 2023. PMID: 37868151 Free PMC article.
A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity.
Karnell JL, Albulescu M, Drabic S, Wang L, Moate R, Baca M, Oganesyan V, Gunsior M, Thisted T, Yan L, Li J, Xiong X, Eck SC, de Los Reyes M, Yusuf I, Streicher K, Müller-Ladner U, Howe D, Ettinger R, Herbst R, Drappa J. Karnell JL, et al. Among authors: moate r. Sci Transl Med. 2019 Apr 24;11(489):eaar6584. doi: 10.1126/scitranslmed.aar6584. Sci Transl Med. 2019. PMID: 31019027
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Pharmacokinetics, Immunogenicity, Safety, and Tolerability After Subcutaneous Administration of Tozorakimab in Healthy Chinese Participants.
Li Y, Zhang H, Pandya H, Miao L, Reid F, Jimenez E, Sadiq MW, Moate R, Lei A, Zhou XH, Kell C, Ding J, Zhang G, Zhao L, Ge X. Li Y, et al. Among authors: moate r. Clin Pharmacol Drug Dev. 2024 Mar 25. doi: 10.1002/cpdd.1391. Online ahead of print. Clin Pharmacol Drug Dev. 2024. PMID: 38523487
27 results